Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma

J Asthma. 2007 Apr;44(3):195-6. doi: 10.1080/02770900701209749.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Aged
  • Anti-Asthmatic Agents / administration & dosage*
  • Anti-Asthmatic Agents / adverse effects
  • Anti-Asthmatic Agents / therapeutic use
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Asthma / blood
  • Asthma / drug therapy*
  • Asthma / etiology
  • Asthma / immunology*
  • Female
  • Home Care Services*
  • Humans
  • Hypersensitivity / complications*
  • Immunoglobulin E / blood
  • Immunoglobulin E / immunology*
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Omalizumab
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Anti-Asthmatic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Omalizumab
  • Immunoglobulin E